TNF -Alpha Modulating Benzimidazoles
US-2015152065-A1 · Jun 4, 2015 · US
Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical uses thereof
US11512055B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11512055-B2 |
| Application number | US-201917052451-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 3, 2019 |
| Priority date | May 3, 2018 |
| Publication date | Nov 29, 2022 |
| Grant date | Nov 29, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to benzimidazole derivatives of formula (I) as inhibitors of retinoid-related orphan receptor gamma (RORγ) protein, pharmaceutical compositions containing the compounds, preparation methods thereof, and the use of the compounds as therapeutic agents for the treatment of RORγ-mediated diseases or disorders.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the compound is selected from the group consisting of: 2. A pharmaceutical composition comprising a compound of claim 1 , or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.
Assignees
Inventors
Classifications
Halogen atoms or nitro radicals · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Drugs for immunological or allergic disorders · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
with a three-membered ring · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11512055B2 cover?
- The present invention relates to benzimidazole derivatives of formula (I) as inhibitors of retinoid-related orphan receptor gamma (RORγ) protein, pharmaceutical compositions containing the compounds, preparation methods thereof, and the use of the compounds as therapeutic agents for the treatment of RORγ-mediated diseases or disorders.
- Who is the assignee on this patent?
- Jiangsu Hengrui Medicine Co, Shanghai hengrui pharmaceutical co ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4184. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).